See every trial and approval built around a cancer biomarker.
10 biomarkers, matched against every interventional cancer trial on ClinicalTrials.gov and every FDA and EU approval we track. Updated 2026-10-27.
EGFR mutation must be an Ex19del or Ex21 L858R substitution.
Biomarkers
| Biomarker | Active trials | Recruiting | FDA approvals | EU approvals |
|---|---|---|---|---|
| Mutations | ||||
| EGFR L858RNSCLC | 420 | 201 | 16 | 13 |
| EGFR exon 19 deletionNSCLC | 411 | 196 | 16 | 13 |
| KRAS G12CNSCLC, colorectal, pancreatic | 253 | 145 | 4 | 2 |
| BRAF V600Emelanoma, colorectal, NSCLC, thyroid, tumor-agnostic | 196 | 104 | 17 | 13 |
| BRCA1/2 mutationbreast, ovarian, prostate, pancreatic | 168 | 83 | 15 | 9 |
| Fusions | ||||
| ALK fusionNSCLC, ALCL, IMT | 192 | 91 | 9 | 13 |
| ROS1 fusionNSCLC | 61 | 34 | 5 | 3 |
| NTRK1/2/3 fusiontumor-agnostic | 36 | 25 | 3 | 3 |
| Protein expression | ||||
| HER2-low / ultralow (IHC 1+ or 2+/ISH-)breast | 124 | 75 | 2 | 2 |
| Genomic signatures | ||||
| MSI-H / dMMRcolorectal, endometrial, tumor-agnostic | 240 | 110 | 16 | 9 |
Counts include trials that ask for a broader group containing the biomarker, such as "sensitizing EGFR mutation". Approvals count each approved indication separately.